Glucagonoma history and symptoms: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Jyostna Chouturi (talk | contribs)
nocaptcha
9,554 edits
No edit summary
Parminder Dhingra (talk | contribs)
CMEUser, nocaptcha, Administrators
2,909 edits
Line 6: Line 6:


==History and Symptoms==
==History and Symptoms==
* The primary [[physiology|physiological]] effect of glucagonoma is an overproduction of the [[peptide]] hormone [[glucagon]], which enhances [[blood glucose]] levels through the activation of [[catabolism|catabolic]] processes including [[gluconeogenesis]] and [[lipolysis]]. Gluconeogenesis produces [[glucose]] from [[protein]] and [[amino acid]] materials; lipolysis is the breakdown of [[adipose tissue|fat]]. The net result is hyperglucagonemia, decreased blood levels of [[amino acid]]s (hypoaminoacidemia), [[anemia]], [[diarrhea]], and weight loss of 5-15 [[kilogram|kg]].
* [[Necrolytic migratory erythema]] (NME) is a classical symptom observed in patients with glucagonoma and is present in 80% of cases. Associated NME is characterized by the spread of erythematous blisters and swelling across areas subject to greater friction and pressure, including the lower [[abdomen]], [[buttock]]s, [[perineum]], and [[groin]].
* [[Necrolytic migratory erythema]] (NME) is a classical symptom observed in patients with glucagonoma and is present in 80% of cases. Associated NME is characterized by the spread of erythematous blisters and swelling across areas subject to greater friction and pressure, including the lower [[abdomen]], [[buttock]]s, [[perineum]], and [[groin]].
* [[Diabetes mellitus]] also frequently results from the [[insulin]] and [[glucagon]] imbalance that occurs in glucagonoma.<ref>{{cite journal |author=Koike N, Hatori T, Imaizumi T, ''et al'' |title=Malignant glucagonoma of the pancreas diagnoses through anemia and diabetes mellitus |journal=Journal of hepato-biliary-pancreatic surgery |volume=10 |issue=1 |pages=101-5 |year=2003 |pmid=12918465 |doi=}}</ref> Diabetes mellitus is present in 80-90% of cases of glucagonoma, and is exacerbated by preexisting [[insulin resistance]].


==References==
==References==

Revision as of 17:57, 8 October 2015

Glucagonoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Glucagonoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glucagonoma history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glucagonoma history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glucagonoma history and symptoms

CDC on Glucagonoma history and symptoms

Glucagonoma history and symptoms in the news

Blogs on Glucagonoma history and symptoms

Directions to Hospitals Treating Glucagonoma

Risk calculators and risk factors for Glucagonoma history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

History and Symptoms

  • Necrolytic migratory erythema (NME) is a classical symptom observed in patients with glucagonoma and is present in 80% of cases. Associated NME is characterized by the spread of erythematous blisters and swelling across areas subject to greater friction and pressure, including the lower abdomen, buttocks, perineum, and groin.

References


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Glucagonoma_history_and_symptoms&oldid=1171887"